# Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

> **NCT05935176** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **CanSino Biologics Inc.** · enrollment: 660 (actual)

## Conditions studied

- Epidemic Meningitis

## Interventions

- **BIOLOGICAL:** MCV4
- **BIOLOGICAL:** MCV4
- **BIOLOGICAL:** MCV4

## Key facts

- **NCT ID:** NCT05935176
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-20
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-07-15
- **Target enrollment:** 660 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935176, "Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05935176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*